Abstract:In the past few years the medical treatment of malignant diseases has steadily increased in scope and importance. However, the tumor regimens described in the textbooks still are rather schematic recommendations, which are inadequately tailored to the needs of the individual case. Current tumor therapy is based on the results of the statistical analysis using empirical data collected in randomized trials. While patients can today be given a statistical value which expresses their computed chance of a cure versus that of a defined population, there is still no generally valid method which could serve as a rational basis for individualized counselling. But cytostatic chemotherapy has yet another major shortcoming: the collective assessment of toxicity, which is related to one of the basic properties of cytostatic drugs, i.e. their extremely low therapeutic index. Many of the side effects of cytostatics may cause severe irreversible, at times even fatal, organ dysfunction. Consequently, the definition of the therapeutic risks involved on the basis of an objective identification of potential organ toxicity is a major challenge. "Surgery without a knife", as K.H. Spitzy has called chemotherapy, should be subjected to objective criteria for its indications and contraindications so that patients can truly benefit from what are become increasingly aggressive measures. The principle of weighing the benefits desired in the individual case against the potential risks involved in a specific treatment, which Paul Ehrlich postulated for antibacterial chemotherapy, should also be applied to cytostatic chemotherapy with a view to facilitating the decision for or against therapy in borderline cases. The present contribution which is designed to shed light on the cardiotoxicity of doxorubicin should be interpreted in light of this situation. Pathogenetic aspects and animal experiments on drug-induced lipid peroxidation will be discussed and clinical trials on both acute and chronic doxorubicin cardiotoxicity will be reviewed. Special attention will be paid to the tolerable risks of this special form of toxicity and cardiologic methods currently available for patient monitoring will be critically assessed. In summary, the studies produced the following results: A. Pathogenesis Treatment of C 57 B1 mice with doxorubicin increases the production of malonic dialdehyde in the myocardium. Enhanced malonic dialdehyde production can largely be suppressed by the additional administration of anti-oxidants (tocopherol, glutathione, cysteamine, cysteine).(ABSTRACT TRUNCATED AT 400 WORDS)

Prevention of Doxorubicin Cardiopathic Changes by a Benzyl Styryl Sulfone in Mice.

Small-molecule mediated MuRF1 inhibition protects from doxorubicin-induced cardiac atrophy and contractile dysfunction

Early Transcriptional Changes in Cardiac Mitochondria During Chronic Doxorubicin Exposure and Mitigation by Dexrazoxane in Mice.

Chemical Endoplasmic Reticulum Chaperone Alleviates Doxorubicin-Induced Cardiac Dysfunction

Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo

Amidization of Doxorubicin Alleviates Doxorubicin-Induced Contractile Dysfunction and Reduced Survival in Murine Cardiomyocytes.

Uric acid preconditioning alleviated doxorubicin induced JNK activation and Cx43 phosphorylation associated cardiotoxicity via activation of AMPK-SHP2 signaling pathway

[Selective toxicity of cytostatic agents: studies on the cardiotoxicity of doxorubicin, its pathogenesis and contraindications]

Ginsenoside Rg1 Prevents Doxorubicin-Induced Cardiotoxicity Through The Inhibition Of Autophagy And Endoplasmic Reticulum Stress In Mice

Primary Protection of Diosmin Against Doxorubicin Cardiotoxicity via Inhibiting Oxido-Inflammatory Stress and Apoptosis in Rats

Targeting Heat Shock Protein 47 Alleviated Doxorubicin-Induced Cardiotoxicity and Remodeling in Mice Through Suppression of the NLRP3 Inflammasome.

Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy

Prevention Against and Treatment of Doxorubicin-Induced Acute Cardiotoxicity by Dexrazoxane and Schisandrin B

Astragalus Polysaccharide Restores Autophagic Flux and Improves Cardiomyocyte Function in Doxorubicin-Induced Cardiotoxicity

Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress

GPR91 Receptor Mediates Protection against Doxorubicin-Induced Cardiotoxicity without Altering Its Anticancer Efficacy. An In Vitro Study on H9C2 Cardiomyoblasts and Breast Cancer-Derived MCF-7 Cells

A Novel Danshensu Derivative Prevents Cardiac Dysfunction and Improves the Chemotherapeutic Efficacy of Doxorubicin in Breast Cancer Cells

Ginsenoside Rh2 mitigates doxorubicin-induced cardiotoxicity by inhibiting apoptotic and inflammatory damage and weakening pathological remodelling in breast cancer-bearing mice

AstragalusPolysaccharide Suppresses Doxorubicin-Induced Cardiotoxicity by Regulating the PI3k/Akt and P38mapk Pathways

Low Dose Radiation Prevents Doxorubicin-Induced Cardiotoxicity.

Breviscapine Remodels Myocardial Glucose and Lipid Metabolism by Regulating Serotonin to Alleviate Doxorubicin-Induced Cardiotoxicity